Novo Nordisk ADR (NYSE:NVO) shares, rose in value, with the stock price up by 0.06% to the previous day’s close as strong demand from buyers drove the stock to $78.88.
Actively observing the price movement in the recent trading, the stock is buoying the session at $78.83, falling within a range of $78.41 and $79.0663. The value of beta (5-year monthly) is 0.165 whereas the PE ratio is 24.03 over 12-month period. Referring to stock’s 52-week performance, its high was $148.15, and the low was $78.17. On the whole, NVO has fluctuated by -4.88% over the past month.
With the market capitalization of Novo Nordisk ADR currently standing at about $265.50 billion, investors are eagerly awaiting this quarter’s results, scheduled for in March. The company’s Forward Dividend Ratio is 1.45, with its dividend yield at 1.83%.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 351.65B, with a low estimate of 80.49B and a high estimate of 82.34B. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 81.67B.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NVO’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 1.29, with the price of NVO currently trading nearly -5.40% and -13.01% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.70, while the 7-day volatility ratio is showing 2.31% which for the 30-day chart, stands at 2.41%. Furthermore, Novo Nordisk ADR (NVO)’s beta value is 0.44, and its average true range (ATR) is 2.71.
A comparison of Novo Nordisk ADR (NVO) with its peers suggests the former has fared considerably weaker in the market. NVO showed an intraday change of 0.06% in today’s session so far, and over the past year, it shrunk by -34.27%%.
Data on historical trading for Novo Nordisk ADR (NYSE:NVO) indicates that the trading volumes over the past 10 days have averaged 8.71 and over the past 3 months, they’ve averaged 8.28 million. According to company’s latest data on outstanding shares, there are 3.37 billion shares outstanding.
Nearly 0.03% of Novo Nordisk ADR’s shares belong to company insiders and institutional investors own 10.22% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 8.27 million shares as on 2025-01-15, resulting in a short ratio of 0.85. According to the data, the short interest in Novo Nordisk ADR (NVO) stood at 26.00 of shares outstanding as of 2025-01-15; the number of short shares registered in 2024-12-13 reached 4.7 million. The stock has fallen by -8.31% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NVO stock heading into the next quarter.
